Randomized Clinical Trial Comparing Effects of Pulsatile vs Nonpulsatile Cardiopulmonary Bypass on Neurologic Outcomes.

Ann Thorac SurgMay 11, 2026 (epub)

Srihari Rajesh, Kevsergül Dayi, Marc J Lussier et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of pulsatile versus nonpulsatile cardiopulmonary bypass on S100B levels and neurological outcomes in pediatric patients undergoing congenital heart surgery. Among 144 patients, S100B levels were similar across both perfusion modalities, and 36 patients experienced neural injuries, with no significant differences in outcomes related to the type of perfusion used.

Key findings

  • S100B levels were similar between pulsatile and nonpulsatile perfusion at all measured time points.
  • A total of 36 patients experienced neural injuries, with 15 in the nonpulsatile group and 21 in the pulsatile group.
  • S100B levels rose during CPB, peaking before weaning and 1 hour after CPB.
  • 24-hour S100B levels showed a weak association with clinical outcomes.

Why it matters

Understanding the impact of different perfusion modalities on neurological outcomes is crucial for optimizing care in pediatric patients undergoing congenital heart surgery. This study suggests that the choice of perfusion may not significantly influence neural injury risk as measured by S100B levels.

Source

Published in Ann Thorac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.